Trial reportArchives of ophthalmology (Chicago, Ill. : 1960)2009
Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.
Trial report in Archives of ophthalmology (Chicago, Ill. : 1960), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00559936 (Effectiveness and Safety of Topical Bevacizumab), which is not on this map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Who cites it
83 citing papers in PubMed, 197 citations in OpenAlex.
- Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal tem cell deficiency: a phase I/II clinical trial of the first xenobiotic-free, serum-free, antibiotic-free manufacturing protocol developed in the US.Nature communications · 2025Trial
- Bevacizumab in High-Risk Corneal Transplantation: A Pilot Multicenter Prospective Randomized Control Trial.Ophthalmology · 2022Trial
- Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.Investigative ophthalmology & visual science · 2013Trial
- Targeting injury-induced transglutaminase-2 activity with a cementoin-SLPI fusion protein: a novel therapeutic strategy for alkali-induced corneal injury.Journal of translational medicine · 2026Review
- Topical Application of Preserved and Unpreserved Bevacizumab Eye Drops Improves Ocular Surface Parameters in Dogs with Chronic Keratitis: A Pilot Study.Veterinary sciences · 2026Article
- Molecular Pathways Driving Corneal Neovascularization in Herpes Simplex Keratitis.Pathogens (Basel, Switzerland) · 2026Review
- Risk factors and survival analysis in high-risk penetrating keratoplasty: a retrospective cohort study in 220 patients.BMC ophthalmology · 2026Article
- Review
- Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Preserved bevacizumab (Avastin®) eye drops for application in multidose containers - an in-vitro characterisation.BMC veterinary research · 2025Article
- Anti-vascular endothelial growth factor therapies in ophthalmology.Medical hypothesis, discovery & innovation ophthalmology journal · 2025Review
- Clinical Outcomes of Topical Bevacizumab for the Treatment of Corneal Neovascularization.Cureus · 2024Article
- Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno-associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation.Journal of ophthalmology · 2024Review
- Sustained Inhibition of VEGF and TNF-α Achieves Multi-Ocular Protection and Prevents Formation of Blood Vessels after Severe Ocular Trauma.Pharmaceutics · 2023Article
- The use of aflibercept (VEGF trap) in mitigating sulfur mustard-induced corneal neovascularization in a rabbit model.Toxicology reports · 2023Article
- Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns.Frontiers in medicine · 2023Article
- Bevacizumab Eye Drops Vs. Intra-meibomian Gland Injection of Bevacizumab for Meibomian Gland Dysfunction-Associated Posterior Blepharitis.Frontiers in medicine · 2022Article
- A Hypothalamic-Controlled Neural Reflex Promotes Corneal Inflammation.Investigative ophthalmology & visual science · 2021Article
- Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics.Molecular therapy. Methods & clinical development · 2021Article
- Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series.Veterinary ophthalmology · 2021Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo study the safety and efficacy of topical bevacizumab in the treatment of corneal neovascularization (NV).
designIn a prospective, open-label, noncomparative study, 10 eyes from 10 patients with stable corneal NV were treated with topical bevacizumab, 1.0%, for 3 weeks and followed up for up to 24 weeks.
main outcome measuresThe primary safety variables were the occurrence of ocular and systemic adverse events throughout the course of the study. The primary efficacy variables were neovascular area, the area of the corneal vessels themselves; vessel caliber, the mean diameter of the corneal vessels; and invasion area, the fraction of the total corneal area covered by the vessels.
resultsFrom baseline visit to the last follow-up visit, mean reductions were 47.1% (standard deviation [SD], 36.7%) for neovascular area, 54.1% (SD, 28.1%) for vessel caliber, and 12.2% (SD, 42.0%) for invasion area. The decreases in neovascular area and vessel caliber were statistically significant (P= .001 and P< .001, respectively). However, changes in invasion area did not achieve statistical significance (P= .19). Visual acuity and central corneal thickness showed no significant changes. Topical bevacizumab was well tolerated with no adverse events.
conclusionsShort-term topical bevacizumab therapy reduces the severity of corneal NV without local or systemic adverse effects. APPLICATION TO CLINICAL PRACTICE: Topical bevacizumab provides an alternative therapy in the treatment of stable corneal NV.
trial registrationclinicaltrials.gov Identifier: NCT00559936.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.